These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20615448)

  • 1. Proteasome inhibitors: Dozens of molecules and still counting.
    de Bettignies G; Coux O
    Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
    Tsukamoto S; Yokosawa H
    Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibitors of proteasome activity.
    Gaczynska M; Osmulski PA
    Methods Mol Biol; 2005; 301():3-22. PubMed ID: 15917622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors.
    Aubin S; Martin B; Delcros JG; Arlot-Bonnemains Y; Baudy-Floc'h M
    J Med Chem; 2005 Jan; 48(1):330-4. PubMed ID: 15634028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors.
    Maréchal X; Pujol A; Richy N; Genin E; Basse N; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2012 Jun; 52():322-7. PubMed ID: 22440858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
    Dalla Via L; Nardon C; Fregona D
    Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery and assay development in the ubiquitin-proteasome system.
    Berkers CR; Ovaa H
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
    Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L
    Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors in multiple myeloma.
    Anderson KC
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition: mechanism of action.
    DeMartino GN
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proteasome and proteolysis].
    Papapostolou D; Reboud-Ravaux M
    J Soc Biol; 2004; 198(3):263-78. PubMed ID: 15662944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent and non-covalent reversible proteasome inhibition.
    Beck P; Dubiella C; Groll M
    Biol Chem; 2012 Oct; 393(10):1101-20. PubMed ID: 23091276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors as therapeutics.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
    Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
    Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors.
    Bayot A; Basse N; Lee I; Gareil M; Pirotte B; Bulteau AL; Friguet B; Reboud-Ravaux M
    Biochimie; 2008 Feb; 90(2):260-9. PubMed ID: 18021745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.